|
Apr 25
|
Here's Why We're Not Too Worried About CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation
|
|
Apr 8
|
CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors
|
|
Apr 3
|
CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
|
|
Mar 21
|
CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors
|
|
Mar 18
|
CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
|
|
Mar 13
|
CytomX Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
|
|
Mar 12
|
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2023 Earnings Call Transcript
|
|
Mar 12
|
Q4 2023 CytomX Therapeutics Inc Earnings Call
|
|
Mar 11
|
CytomX Therapeutics Inc (CTMX) Reports 2023 Financial Results and Provides Pipeline Update
|
|
Mar 11
|
CytomX Therapeutics (CTMX) Lags Q4 Earnings Estimates
|
|
Mar 11
|
CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update
|
|
Mar 4
|
CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024
|
|
Feb 13
|
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) largest shareholders are retail investors with 50% ownership, institutions own 29%
|
|
Jan 15
|
Iovance (IOVA) Surges More Than 150% in 3 Months: Here's Why
|
|
Jan 15
|
Solid Biosciences (SLDB) Rises 271% in 3 Months: Here's Why
|
|
Jan 12
|
Emergent (EBS) Gets $235.8M DoD Contract for Anthrax Vaccine
|
|
Jan 12
|
Amicus (FOLD) Stock Rises More Than 25% in 3 Months: Here's Why
|
|
Jan 12
|
CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference
|
|
Jan 11
|
Aclaris (ACRS) Down 21% on Mixed Results From Eczema Study
|
|
Jan 10
|
Why Sarepta's (SRPT) Stock Price Moved Up 17% on Tuesday
|